Drug Trial Radar · NCT05894707
Evaluate the Safety and Tolerability of SCT650C in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Jun 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
32
Planned (sponsor's estimate)
Start
Jun 2023
Primary completion
Nov 2023
Study completion Mar 2024
Sponsor
- Lead sponsor
- Sinocelltech Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 8, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of clinical trial is to evaluate the safety and tolerability of SCT650C in healthy participants.
Conditions
- Autoimmune Disease
Interventions
SCT650CDrug
Recombinant anti-IL-17A antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: Baseline (Day 1, IP administration) up to 24 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Linear Clinical Research - Joonadalup
Joondalup, Western Australia, Australia
Linear Clinical Research - B Block
Nedlands, Western Australia, Australia
Linear Clinical Research - Harry Perkins
Nedlands, Western Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.